Celgene (CELG) Wins FDA Approval for Pomalyst in Multiple Myeloma
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Join SI Premium – FREE
Celgene Corp (NASDAQ: CELG) is said to have won FDA approval for pomalidomide in multiple myeloma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
